Published in Oncoimmunology on December 01, 2012
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Intricacies for posttranslational tumor-targeted cytokine gene therapy. Mediators Inflamm (2013) 0.78
Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model. EJNMMI Res (2015) 0.76
Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncoimmunology (2014) 0.76
Radiation meets immunotherapy - a perfect match in the era of combination therapy? Int J Radiat Biol (2015) 0.75
The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study. BMC Vet Res (2013) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol (2006) 1.56
The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol (2010) 1.06
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother (1991) (1992) 0.86
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol (2005) 0.96
The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92
MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol (2004) 0.91
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res (2009) 0.80
Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer (2004) 0.75
Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach. Am J Surg (2013) 0.75